{"id":57922,"date":"2026-02-25T14:22:34","date_gmt":"2026-02-25T06:22:34","guid":{"rendered":"https:\/\/flcube.com\/?p=57922"},"modified":"2026-02-25T14:22:35","modified_gmt":"2026-02-25T06:22:35","slug":"novo-nordisk-to-cut-semaglutide-list-prices-by-35-50-wegovy-ozempic-rybelsus-standardized-at-675-month","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57922","title":{"rendered":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month"},"content":{"rendered":"\n<p><strong>Novo Nordisk (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE:\u202fNVO<\/a>)<\/strong> announced that, effective <strong>January\u202f1,\u202f2027<\/strong>, it will <strong>lower Wholesale Acquisition Cost (list prices)<\/strong> across its entire <strong>semaglutide portfolio<\/strong>. The new pricing structure standardizes all doses of <strong>Wegovy<\/strong> (2.4\u202fmg injection, 25\u202fmg tablets), <strong>Ozempic<\/strong> (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and <strong>Rybelsus<\/strong> (7\u202fmg, 14\u202fmg tablets) at <strong>USD\u202f675 per month<\/strong>. The reductions represent <strong>~50% for Wegovy<\/strong> and <strong>~35% for Ozempic<\/strong> from current list prices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pricing-restructuring-overview\">Pricing Restructuring Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Current List Price<\/th><th>New List Price (Jan\u202f2027)<\/th><th>Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>Wegovy<\/strong> (2.4\u202fmg inj, 25\u202fmg tabs)<\/td><td>~USD\u202f1,349\/month<\/td><td><strong>USD\u202f675\/month<\/strong><\/td><td><strong>~50%<\/strong><\/td><\/tr><tr><td><strong>Ozempic<\/strong> (0.5\u202fmg, 1\u202fmg, 2\u202fmg inj)<\/td><td>~USD\u202f1,039\/month<\/td><td><strong>USD\u202f675\/month<\/strong><\/td><td><strong>~35%<\/strong><\/td><\/tr><tr><td><strong>Rybelsus<\/strong> (7\u202fmg, 14\u202fmg tabs)<\/td><td>Variable<\/td><td><strong>USD\u202f675\/month<\/strong><\/td><td>Standardized<\/td><\/tr><tr><td><strong>Portfolio Standardization<\/strong><\/td><td>Multiple price points<\/td><td><strong>USD\u202f675\/month across all doses<\/strong><\/td><td>Simplified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-medicare-price-negotiation-context\">Medicare Price Negotiation Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>CMS Negotiation Round<\/strong><\/td><td>Second round (Nov\u202f2025)<\/td><\/tr><tr><td><strong>Negotiated 30\u2011Day Cost<\/strong><\/td><td><strong>USD\u202f274<\/strong> (all three semaglutide brands)<\/td><\/tr><tr><td><strong>Original List Price<\/strong><\/td><td>USD\u202f959<\/td><\/tr><tr><td><strong>Negotiation Discount<\/strong><\/td><td><strong>~71% reduction<\/strong> from original list price<\/td><\/tr><tr><td><strong>Implication<\/strong><\/td><td>Medicare pricing pressure likely catalyzed commercial list price adjustments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Medicare Alignment:<\/strong> The <strong>USD\u202f675 standardized price<\/strong> bridges the gap between previous commercial list prices and the <strong>USD\u202f274 Medicare negotiated rate<\/strong>, potentially reducing political and public scrutiny while preserving margin above government pricing.<\/li>\n\n\n\n<li><strong>Market Access Expansion:<\/strong> Lower list prices may improve <strong>payer formulary positioning<\/strong>, reduce prior authorization barriers, and expand patient access\u2014particularly for cash\u2011pay and under\u2011insured populations.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Pricing pressure from <strong>Eli Lilly&#8217;s tirzepatide (Zepbound, Mounjaro)<\/strong> and anticipated <strong>oral GLP\u20111 competitors<\/strong> necessitates proactive price positioning to defend market share.<\/li>\n\n\n\n<li><strong>Portfolio Simplification:<\/strong> <strong>Single price point across all doses and brands<\/strong> reduces administrative complexity and may streamline contracting with pharmacy benefit managers (PBMs).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue Implications<\/strong><\/td><td>Lower list prices may compress top\u2011line growth; volume expansion and PBM rebate restructuring could offset margin pressure<\/td><\/tr><tr><td><strong>Patient Affordability<\/strong><\/td><td>~50% Wegovy reduction addresses obesity treatment access concerns; ~35% Ozempic cut benefits diabetes management<\/td><\/tr><tr><td><strong>Industry Precedent<\/strong><\/td><td>Novo Nordisk joins <strong>Eli Lilly and other peers<\/strong> in proactive price reductions ahead of intensifying policy pressure and competition<\/td><\/tr><tr><td><strong>Stock Market Reaction<\/strong><\/td><td>Investor focus on volume growth trajectory and ability to maintain profitability at lower price points<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pricing implementation, volume response, and revenue impact for the semaglutide portfolio. Actual results may differ due to risks including competitive pricing actions, formulary exclusion threats, and policy changes affecting drug reimbursement.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57923,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,4445,148,860,86,75],"class_list":["post-57922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-metabolic-disease","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-price-negotiations"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57922\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57922\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T06:22:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T06:22:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\\\/Month\",\"datePublished\":\"2026-02-25T06:22:34+00:00\",\"dateModified\":\"2026-02-25T06:22:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2504.webp\",\"keywords\":[\"Diabetes\",\"Metabolic disease\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"Price negotiations\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57922#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57922\",\"name\":\"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\\\/Month - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2504.webp\",\"datePublished\":\"2026-02-25T06:22:34+00:00\",\"dateModified\":\"2026-02-25T06:22:35+00:00\",\"description\":\"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57922\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2504.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\\\/Month\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57922#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\\\/Month\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57922","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month","og_description":"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.","og_url":"https:\/\/flcube.com\/?p=57922","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T06:22:34+00:00","article_modified_time":"2026-02-25T06:22:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57922#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57922"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month","datePublished":"2026-02-25T06:22:34+00:00","dateModified":"2026-02-25T06:22:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57922"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57922#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","keywords":["Diabetes","Metabolic disease","Novo Nordisk","NYSE: NVO","Obesity","Price negotiations"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57922#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57922","url":"https:\/\/flcube.com\/?p=57922","name":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57922#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57922#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","datePublished":"2026-02-25T06:22:34+00:00","dateModified":"2026-02-25T06:22:35+00:00","description":"Novo Nordisk (NYSE:\u202fNVO) announced that, effective January\u202f1,\u202f2027, it will lower Wholesale Acquisition Cost (list prices) across its entire semaglutide portfolio. The new pricing structure standardizes all doses of Wegovy (2.4\u202fmg injection, 25\u202fmg tablets), Ozempic (0.5\u202fmg, 1\u202fmg, 2\u202fmg injections), and Rybelsus (7\u202fmg, 14\u202fmg tablets) at USD\u202f675 per month. The reductions represent ~50% for Wegovy and ~35% for Ozempic from current list prices.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57922#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57922"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57922#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","width":1080,"height":608,"caption":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57922#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk to Cut Semaglutide List Prices by 35\u201150% \u2013 Wegovy, Ozempic, Rybelsus Standardized at $675\/Month"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57922"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57922\/revisions"}],"predecessor-version":[{"id":57925,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57922\/revisions\/57925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57923"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}